PM vs RLX: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: RLX is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. PM and RLX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined PM and RLX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Philip Morris International is one of the world's largest tobacco and nicotine companies, selling Marlboro and other cigarette brands across roughly 180 markets outside the United States. A 2008 spin-off from Altria split the Marlboro trademark by geography: Altria sells it in the US, while PMI owns it everywhere else. What sets PMI apart today is the scale of its pivot away from combustible cigarettes. Its smoke-free portfolio, led by IQOS heated tobacco, ZYN nicotine pouches (gained through the 2023 Swedish Match acquisition), and VEEV vapes, reached about 43% of net revenues in early 2026 and is available in more than 100 markets. In Q1 2026 IQOS shipment volume grew double digits and surpassed Marlboro to become the company's number one nicotine brand by volume in the markets where it competes.

Full PM guide

RLX Technology Inc. designs and sells closed-system e-vapor devices and pods, plus a growing disposable line, under the RELX brand. It began as the dominant player in China's domestic vaping market, then was reshaped almost overnight when Beijing imposed a national product standard in 2022 that banned non-tobacco flavors, created a licensing regime and layered on a 36% consumption tax. Domestic revenue fell hard. Management responded by pushing the business overseas, and international markets across Europe, Southeast Asia and elsewhere now carry the growth. Manufacturing is largely outsourced to Chinese contract producers, so the company operates asset-light, with brand, product design and channel relationships as the assets that matter.

Full RLX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• PM drivers: IQOS heated tobacco leadership; ZYN and the US oral-nicotine pouch push.
• RLX drivers: International expansion carrying the growth; Margin recovery and operating leverage.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Regulation is the dominant risk: tobacco and nicotine face constant scrutiny, and the US FDA's stance on nicotine pouches, flavors, and youth use could restrict or slow ZYN and other products in PMI's most promising growth market. For RLX, regulation is the dominant risk and it arrives from multiple directions at once: China's flavor ban, licensing regime and 36% consumption tax already reset the domestic business, and overseas the UK, France and several EU states have moved against disposables while flavor restrictions spread.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick PM if you believe its drivers more; RLX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the PM and RLX guides.

PM. Figures are approximate and tied to the asOf date; verify live numbers before acting. PMI tends to trade at a premium to slower-growing tobacco peers like Altria because IQOS and ZYN give it a real growth angle, so the multiple reflects the transition story as much as current earnings. Analysts favor its faster EPS growth, but that view assumes smoke-free momentum continues and regulation stays manageable.

RLX. RLX reports in renminbi; the dollar figures above are approximate conversions at prevailing rates and will shift with the exchange rate. The trailing multiple of roughly 19 times looks ordinary until the cash is netted out, at which point the operating business is being valued at a small fraction of the headline market cap. Whether that discount is an opportunity or a fair price for regulatory and jurisdictional risk is the entire argument over the stock. Figures reflect results through the March 2026 quarter and market data as of August 2026.

Headline figures (approximate, Jul 2026): PM shows revenue (ttm) ~$40 billion, growing high single digits; Q1 2026 net revenues rose about 9% year over year, smoke-free mix / drivers Smoke-free products ~43% of net revenues, led by IQOS heated tobacco and ZYN nicotine pouches; IQOS is now the top nicotine brand by volume in its markets, margins / profitability Strong, staple-like margins; adjusted EPS guided to low-double-digit growth in 2026, faster than most consumer-staples peers, dividend Yield well above the broad market (roughly high-3% range), raised every year since the 2008 spin-off; higher payout ratio than some peers; RLX shows market cap ~$2.5B, revenue (ttm) ~RMB 4.7B (~$635M), up ~63%, net income (ttm) ~$143M, cash and investments, net of debt ~RMB 14B (~$2.0B).

PM and RLX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined PM and RLX exposure against your real portfolio. It is not an investment adviser.